Price
$29.45
Increased by +2.35%
Dollar volume (20D)
87.11 M
ADR%
4.64
Earnings report date
Oct 30, 2025
Shares float
135.14 M
Shares short
23.44 M [17.35%]
Shares outstanding
158.67 M
Market cap
4.67 B
Beta
1.95
Price/earnings
77.49
20D range
25.28 37.61
50D range
25.28 39.73
200D range
22.92 46.48

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

Its research pipeline includes various investigational medicines.

The company has license agreements with LFB BiotechnologiesS. A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Reported date EPSChange YoY EstimateSurprise
Aug 4, 25 0.17
Increased by +325.00%
0.19
Decreased by -10.53%
Apr 29, 25 0.03
Increased by +142.86%
0.17
Decreased by -82.76%
Feb 26, 25 0.15
Increased by +250.00%
0.09
Increased by +66.67%
Nov 4, 24 0.02
Decreased by -97.26%
0.03
Decreased by -33.33%
Aug 6, 24 0.04
Increased by +111.76%
-0.05
Increased by +180.00%
May 1, 24 -0.07
Increased by +75.00%
-0.04
Decreased by -75.00%
Feb 28, 24 -0.10
Increased by +74.36%
-0.10
Nov 1, 23 0.73
Increased by +380.77%
0.12
Increased by +508.33%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 141.15 M
Increased by +92.13%
28.19 M
Increased by +309.75%
Increased by +19.97%
Increased by +113.27%
Mar 31, 25 120.86 M
Increased by +90.40%
5.06 M
Increased by +147.26%
Increased by +4.19%
Increased by +124.82%
Dec 31, 24 108.19 M
Increased by +146.04%
23.33 M
Increased by +261.84%
Increased by +21.57%
Increased by +165.78%
Sep 30, 24 83.88 M
Decreased by -49.41%
3.88 M
Decreased by -96.59%
Increased by +4.63%
Decreased by -93.27%
Jun 30, 24 73.47 M
Increased by +357.05%
6.88 M
Increased by +114.45%
Increased by +9.36%
Increased by +103.16%
Mar 31, 24 63.47 M
Increased by +713.46%
-10.71 M
Increased by +72.28%
Decreased by -16.87%
Increased by +96.59%
Dec 31, 23 43.97 M
Increased by +54.86 K%
-14.42 M
Increased by +72.80%
Decreased by -32.79%
Increased by +99.95%
Sep 30, 23 165.81 M
Increased by +176.30 K%
113.93 M
Increased by +410.66%
Increased by +68.71%
Increased by +100.18%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY